{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:22:11Z","timestamp":1783506131139,"version":"3.55.0"},"reference-count":105,"publisher":"MDPI AG","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPMA"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p>\n                    Foot complications are common in diabetic patients; foot ulcers are among the more serious consequences. These ulcers frequently become infected, and if not treated promptly and appropriately, diabetic foot infections can lead to septic gangrene and amputation. Foot infections may be classified as mild, moderate, or severe; this largely determines the approach to therapy.\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    is the most common pathogen in these infections, and the increasing incidence of methicillin-resistant\n                    <jats:italic>S aureus<\/jats:italic>\n                    during the past two decades has further complicated antibiotic treatment. Chronic infections are often polymicrobial. Physiologic changes, and local and systemic inflammation, can affect the plasma and tissue pharmacokinetics of antimicrobial agents in diabetic patients, leading to impaired target-site penetration. Knowledge of the serum and tissue concentrations of antibiotics in diabetic patients is, therefore, important for choosing the optimal drug and dose. This article reviews the commonly used therapeutic options for treatment, including many newer antibiotics developed to target multidrug-resistant gram-positive bacteria, and includes available data relating specifically to the tissue penetration of these agents. (J Am Podiatr Med Assoc 100(1): 52\u201363, 2010)\n                  <\/jats:p>","DOI":"10.7547\/1000052","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T09:52:19Z","timestamp":1396345939000},"page":"52-63","source":"Crossref","is-referenced-by-count":26,"title":["Therapeutic Options for Diabetic Foot Infections"],"prefix":"10.3390","volume":"100","author":[{"given":"David P.","family":"Nicolau","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Michigan State University, East Lansing, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"R1","series-title":"Diabetes Care","first-page":"1354","volume":"22","year":"1999","unstructured":"Consensus Development Conference on Diabetic Foot Wound Care: 7\u20138 April 1999, Boston, Massachusetts. American Diabetes Association. .Diabetes Care22::1354. ,1999. .10480782"},{"key":"R2","series-title":"South Med J","first-page":"10","volume":"95","year":"2002","unstructured":"Levin ME: Management of the diabetic foot: preventing amputation. .South Med J95::10. ,2002. .11827238"},{"key":"R3","year":"1997","unstructured":"Boulton AJM: \u201cFoot Problems in Patients with Diabetes Mellitus,\u201d in Textbook of Diabetes, ed by JC Pickup, G Williams, p 58, Blackwell Science, Oxford, England. ,1997. ."},{"key":"R4","series-title":"Diabetes Care","first-page":"382","volume":"22","year":"1999","unstructured":"Ramsey SD, Newton K, Blough D, et al: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. .Diabetes Care22::382. ,1999. .10097914"},{"key":"R5","series-title":"Neurology","first-page":"817","volume":"43","year":"1993","unstructured":"Dyck PJ, Kratz KM, Karnes JL, et al: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. .Neurology43::817. ,1993. .8469345"},{"key":"R6","series-title":"Diabetes Care","first-page":"113","volume":"25","year":"2002","unstructured":"Dolan NC, Liu K, Criqui MH, et al: Peripheral artery disease, diabetes, and reduced lower extremity functioning. .Diabetes Care25::113. ,2002. .11772911"},{"key":"R7","series-title":"J Am Coll Cardiol","first-page":"921","volume":"47","year":"2006","unstructured":"Marso SP, Hiatt WR: Peripheral arterial disease in patients with diabetes. .J Am Coll Cardiol47::921. ,2006. .16516072"},{"key":"R8","series-title":"Diabetologia","first-page":"A39","volume":"34","year":"1991","unstructured":"Cavanagh P, Young M, Adams J, et al: Correlates of structure and function in neuropathic diabetic feet [abstract]. .Diabetologia34: (suppl 2):A39. ,1991. ."},{"key":"R9","series-title":"Foot","first-page":"67","volume":"2","year":"1992","unstructured":"Boulton A: Peripheral neuropathy and the diabetic foot. .Foot2::67. ,1992. ."},{"key":"R10","series-title":"N Engl J Med","first-page":"787","volume":"343","year":"2000","unstructured":"Sumpio BE: Foot ulcers. .N Engl J Med343::787. ,2000. .10984568"},{"key":"R11","series-title":"Circulation","first-page":"44","volume":"96","year":"1997","unstructured":"Murabito JM, D\u2019Agostino RB, Silbershatz H, et al: Intermittent claudication: a risk profile from the Framingham Heart Study. .Circulation96::44. ,1997. .9236415"},{"key":"R12","series-title":"Am J Med","first-page":"236","volume":"116","year":"2004","unstructured":"Al-Delaimy WK, Merchant AT, Rimm EB, et al: Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. .Am J Med116::236. ,2004. .14969651"},{"key":"R13","series-title":"Pract Diabetes Int","first-page":"163","volume":"16","year":"1999","unstructured":"Elhadd TA, Robb R, Jung RT, et al: Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. .Pract Diabetes Int16::163. ,1999. ."},{"key":"R14","series-title":"JAMA","first-page":"1317","volume":"286","year":"2001","unstructured":"Hirsch AT, Criqui MH, Treat-Jacobson D, et al: Peripheral arterial disease detection, awareness, and treatment in primary care. .JAMA286::1317. ,2001. .11560536"},{"key":"R15","series-title":"Am J Med","first-page":"439","volume":"72","year":"1982","unstructured":"Rayfield EJ, Ault MJ, Keusch GT, et al: Infection and diabetes: the case for glucose control. .Am J Med72::439. ,1982. .7036735"},{"key":"R16","series-title":"Diabetes Care","first-page":"256","volume":"15","year":"1992","unstructured":"Marhoffer W, Stein M, Maeser E, et al: Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. .Diabetes Care15::256. ,1992. .1547682"},{"key":"R17","series-title":"Surg Clin North Am","first-page":"769","volume":"64","year":"1984","unstructured":"McMurry JF Jr: Wound healing with diabetes mellitus: better glucose control for better wound healing in diabetes. .Surg Clin North Am64::769. ,1984. .6433493"},{"key":"R18","series-title":"Diabetes","first-page":"880","volume":"25","year":"1976","unstructured":"Molenaar DM, Palumbo PJ, Wilson WR, et al: Leukocyte chemotaxis in diabetic patients and their nondiabetic first degree relatives. .Diabetes25: (suppl):880. ,1976. .971792"},{"key":"R19","series-title":"Plast Reconstr Surg","first-page":"212S","volume":"117","year":"2006","unstructured":"Lipsky BA, Berendt AR, Deery HG, et al: Diagnosis and treatment of diabetic foot infections. .Plast Reconstr Surg117::212S. ,2006. .16799390"},{"key":"R20","series-title":"Presse Med","first-page":"491","volume":"34","year":"2005","unstructured":"Loan CA, Legout L, Assal M, et al: Severe Streptococcus agalactiae infection of the diabetic foot: a deleterious role of Streptococcus agalactiae?. Presse Med34::491. ,2005. ."},{"key":"R21","series-title":"J Diabetes Complications","first-page":"138","volume":"19","year":"2005","unstructured":"Abdulrazak A, Bitar ZI, Al-Shamali AA, et al: Bacteriological study of diabetic foot infections. .J Diabetes Complications19::138. ,2005. .15866058"},{"key":"R22","series-title":"Indian J Pathol Microbiol","first-page":"15","volume":"45","year":"2002","unstructured":"Chincholikar DA, Pal RB: Study of fungal and bacterial infections of the diabetic foot. .Indian J Pathol Microbiol45::15. ,2002. .12593559"},{"key":"R23","series-title":"Saudi Med J","first-page":"344","volume":"21","year":"2000","unstructured":"El-Tahawy AT: Bacteriology of diabetic foot. .Saudi Med J21::344. ,2000. .11533815"},{"key":"R24","series-title":"Diabetes Care","first-page":"1727","volume":"29","year":"2006","unstructured":"Gadepalli R, Dhawan B, Sreenivas V, et al: A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. .Diabetes Care29::1727. ,2006. .16873771"},{"key":"R25","series-title":"J Assoc Physicians India","first-page":"1013","volume":"50","year":"2002","unstructured":"Viswanathan V, Jasmine JJ, Snehalathe C, et al: Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. .J Assoc Physicians India50::1013. ,2002. .12421021"},{"key":"R26","series-title":"Med J Malaysia","first-page":"14","volume":"61","year":"2006","unstructured":"Yoga R, Khairul A, Sunita K, et al: Bacteriology of diabetic foot lesions. .Med J Malaysia61: (suppl A):14. ,2006. .17042222"},{"key":"R27","series-title":"N Engl J Med","first-page":"666","volume":"355","year":"2006","unstructured":"Moran GJ, Krishnadasan A, Gorwitz RJ, et al: Methicillin-resistant S. aureus infections among patients in the emergency department. .N Engl J Med355::666. ,2006. .16914702"},{"key":"R28","series-title":"Eur J Intern Med","first-page":"567","volume":"16","year":"2005","unstructured":"Shankar EM, Mohan V, Premalatha G, et al: Bacterial etiology of diabetic foot infections in South India. .Eur J Intern Med16::567. ,2005. .16314237"},{"key":"R29","series-title":"Diabet Med","first-page":"710","volume":"21","year":"2004","unstructured":"Hartemann-Heurtier A, Robert J, Jacqueminet S, et al: Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. .Diabet Med21::710. ,2004. .15209763"},{"key":"R30","series-title":"Clin Infect Dis","first-page":"889","volume":"39","year":"2004","unstructured":"Lipsky BA, Berendt AR, Deery HG, et al: Diagnosis and treatment of diabetic foot infections. .Clin Infect Dis39::889. ,2004. ."},{"key":"R31","series-title":"J Foot Ankle Surg","first-page":"S1","volume":"45","year":"2006","unstructured":"Frykberg R, Zgonis T, Armstrong A, et al: Diabetic foot disorders: a clinical practice guideline (2006 revision). .J Foot Ankle Surg45::S1. ,2006. .17280936"},{"key":"R32","series-title":"Curr Opin Infect Dis","first-page":"103","volume":"16","year":"2003","unstructured":"Eady EA, Cove JH: Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus: an emerging problem for the management of skin and soft tissue infections. .Curr Opin Infect Dis16::103. ,2003. .12734443"},{"key":"R33","series-title":"Diabet Med","first-page":"159","volume":"20","year":"2003","unstructured":"Dang CN, Prasad YD, Boulton AJ, et al: Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. .Diabet Med20::159. ,2003. .12581269"},{"key":"R34","series-title":"Clin Pharmacokinet","first-page":"477","volume":"6","year":"1991","unstructured":"Gwilt PR, Nahhas RR, Tracewell WG: The effects of diabetes mellitus on pharmacokinetics and pharmocodynamics in humans. .Clin Pharmacokinet6::477. ,1991. ."},{"key":"R35","series-title":"J Chemother","first-page":"648","volume":"18","year":"2006","unstructured":"Tascini C, Gemignani G, Palumbo F, et al: Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. .J Chemother18::648. ,2006. .17267344"},{"key":"R36","year":"1978","unstructured":"Simon VC, Malerczyk V: \u201cSerum and Skin Blister Levels of Cefadroxil in Comparison to Cephalexin,\u201d in Abstracts of the 18th Interscience Conference of Antimicrobial Agents and Chemotherapy, American Society of Microbiology, Washington, DC. ,1978. . Abstract 225."},{"key":"R37","series-title":"J Antimicrob Chemother","first-page":"911","volume":"28","year":"1991","unstructured":"Mouton J, Michel M: Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. .J Antimicrob Chemother28::911. ,1991. .1816187"},{"key":"R38","series-title":"Clin Pharmacol Ther","first-page":"325","volume":"71","year":"2002","unstructured":"Tegeder I, Schmidtko A, Brautigam L, et al: Tissue distribution of imipenem in critically ill patients. .Clin Pharmacol Ther71::325. ,2002. .12011818"},{"key":"R39","series-title":"J Infect Dis","first-page":"77","volume":"142","year":"1980","unstructured":"Wise R, Gillett A, Cadge B: The influence of protein binding upon tissue fluid levels of \u03b2-lactam antibiotics. .J Infect Dis142::77. ,1980. .7400630"},{"key":"R40","series-title":"J Antimicrob Chemother","first-page":"603","volume":"13","year":"1984","unstructured":"Wise R, Bennett S, Dent J: The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin\/clavulanic acid. .J Antimicrob Chemother13::603. ,1984. .6469882"},{"key":"R41","series-title":"Antimicrob Agents Chemother","first-page":"510","volume":"15","year":"1979","unstructured":"Tan JS, Salstrom SJ: Bacampicillin, ampicillin, cephalothin and cephapirin levels in human blood and interstitial fluid. .Antimicrob Agents Chemother15::510. ,1979. .464583"},{"key":"R42","series-title":"Antimicrob Agents Chemother","first-page":"783","volume":"20","year":"1981","unstructured":"Hoffstedt B, Walder M: Influence of serum protein binding and mode of administration on penetration of five cephalosporins into subcutaneous tissue fluid in humans. .Antimicrob Agents Chemother20::783. ,1981. .7325644"},{"key":"R43","series-title":"J Antimicrob Chemother","first-page":"681","volume":"60","year":"2007","unstructured":"Nicolau DP, Sun HK, Seltzer E, et al: Pharmacokinetics of dalbavancin in plasma and skin blister fluid. .J Antimicrob Chemother60::681. ,2007. .17631507"},{"key":"R44","series-title":"Antimicrob Agents Chemother","first-page":"1439","volume":"47","year":"2003","unstructured":"Laethem T, De Lepeleire I, McCrea J, et al: Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. .Antimicrob Agents Chemother47::1439. ,2003. .12654688"},{"key":"R45","series-title":"Antimicrob Agents Chemother","first-page":"31","volume":"46","year":"2002","unstructured":"Wise R, Gee T, Andrews JM, et al: Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. .Antimicrob Agents Chemother46::31. ,2002. .11751107"},{"key":"R46","series-title":"Antimicrob Agents Chemother","first-page":"3941","volume":"52","year":"2008","unstructured":"Kim A, Suecof LA, Sutherland CA, et al: In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. .Antimicrob Agents Chemother52::3941. ,2008. .18779352"},{"key":"R47","series-title":"Antimicrob Agents Chemother","first-page":"3043","volume":"48","year":"2004","unstructured":"Hegde SS, Reyes N, Wiens T, et al: Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. .Antimicrob Agents Chemother48::3043. ,2004. .15273119"},{"key":"R48","series-title":"Antimicrob Agents Chemother","first-page":"1081","volume":"35","year":"1991","unstructured":"Wise R, Logan M, Cooper M, et al: Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. .Antimicrob Agents Chemother35::1081. ,1991. .1656853"},{"key":"R49","series-title":"Antimicrob Agents Chemother","first-page":"123","volume":"28","year":"1895","unstructured":"LeBel M, Gregoire S, Caron M, et al: Difference in blister fluid penetration after single and multiple doses of ceftriaxone. .Antimicrob Agents Chemother28::123. ,1895. ."},{"key":"R50","series-title":"Antimicrob Agents Chemother","first-page":"1352","volume":"44","year":"2000","unstructured":"Trampuz A, Wenk M, Rajacic Z, et al: Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. .Antimicrob Agents Chemother44::1352. ,2000. .10770776"},{"key":"R51","series-title":"Antimicrob Agents Chemother","first-page":"1508","volume":"43","year":"1999","unstructured":"Wise R, Andrews J, Marshall G, et al: Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. .Antimicrob Agents Chemother43::1508. ,1999. .10348784"},{"key":"R52","series-title":"Antimicrob Agents Chemother","first-page":"82","volume":"19","year":"1981","unstructured":"Bruun JN, Ostby N, Bredesen JE, et al: Sulfonamide and trimethoprim concentrations in human serum and skin blister fluid. .Antimicrob Agents Chemother19::82. ,1981. .7247364"},{"key":"R53","series-title":"Chemotherapy","first-page":"261","volume":"31","year":"1985","unstructured":"Schreiner A, Digranes A: Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. .Chemotherapy31::261. ,1985. .4028871"},{"key":"R54","series-title":"Antimicrob Agents Chemother","first-page":"1629","volume":"49","year":"2005","unstructured":"Sun HK, Ong CT, Umer A, et al: Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. .Antimicrob Agents Chemother49::1629. ,2005. .15793157"},{"key":"R55","series-title":"Antimicrob Agents Chemother","first-page":"1843","volume":"45","year":"2001","unstructured":"Gee T, Ellis R, Marshall G, et al: Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. .Antimicrob Agents Chemother45::1843. ,2001. .11353635"},{"key":"R56","series-title":"Surgery","first-page":"671","volume":"110","year":"1991","unstructured":"Seabrook GR, Edmiston CE, Schmit DD, et al: Comparison of serum and tissue antibiotic levels in diabetes-related foot infections. .Surgery110::671. ,1991. .1925956"},{"key":"R57","series-title":"J Antimicrob Chemother","first-page":"581","volume":"31","year":"1993","unstructured":"Duckworth C, Fisher JF, Carter SA, et al: Tissue penetration of clindamycin in diabetic foot infections. .J Antimicrob Chemother31::581. ,1993. .8514652"},{"key":"R58","series-title":"N Engl J Med","first-page":"157","volume":"319","year":"1988","unstructured":"Leclercq R, Derlot E, Duval J, et al: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.. N Engl J Med319::157. ,1988. .2968517"},{"key":"R59","series-title":"J Clin Microbiol","first-page":"5","volume":"41","year":"2003","unstructured":"Cui L, Ma X, Sato K, et al: Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.. J Clin Microbiol41::5. ,2003. .12517819"},{"key":"R60","series-title":"J Clin Microbiol","first-page":"2950","volume":"46","year":"2008","unstructured":"Rybak MJ, Leonard SN, Rossi KL, et al: Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). .J Clin Microbiol46::2950. ,2008. .18632899"},{"key":"R61","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"565","volume":"51","year":"2002","unstructured":"Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin\u2014United States, 2002. .MMWR Morb Mortal Wkly Rep51::565. ,2002. .12139181"},{"key":"R62","series-title":"Circulation","first-page":"2916","volume":"101","year":"2000","unstructured":"Harbarth S, Samore MH, Lichtenberg D, et al: Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. .Circulation101::2916. ,2000. .10869263"},{"key":"R63","series-title":"Antimicrob Agents Chemother","first-page":"1372","volume":"50","year":"2006","unstructured":"Skhirtladze K, Hutschala D, Fleck T, et al: Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. .Antimicrob Agents Chemother50::1372. ,2006. .16569854"},{"key":"R64","series-title":"Clin Infect Dis","first-page":"17","volume":"38","year":"2004","unstructured":"Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam\/amoxicillin-clavulanate. .Clin Infect Dis38::17. ,2004. .14679443"},{"key":"R65","series-title":"Antimicrob Agents Chemother","first-page":"2260","volume":"49","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D, et al; Linezolid CSSTI Study Group: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. .Antimicrob Agents Chemother49::2260. ,2005. .15917519"},{"key":"R66","series-title":"Eur J Clin Pharmacol","first-page":"1093","volume":"64","year":"2008","unstructured":"Majcher-Peszynska J, Haase G, Sass M, et al: Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. .Eur J Clin Pharmacol64::1093. ,2008. .18654767"},{"key":"R67","series-title":"J Antimicrob Chemother","first-page":"819","volume":"60","year":"2007","unstructured":"Stein GE: Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. .J Antimicrob Chemother60::819. ,2007. .17673476"},{"key":"R68","series-title":"Clin Microbiol Infect","first-page":"24","volume":"12","year":"2006","unstructured":"Rybak MJ: The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. .Clin Microbiol Infect12: (suppl 1):24. ,2006. .16445721"},{"key":"R69","series-title":"Expert Opin Investig Drugs","first-page":"1159","volume":"13","year":"2004","unstructured":"Eisenstein BI: Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. .Expert Opin Investig Drugs13::1159. ,2004. .15330747"},{"key":"R70","series-title":"J Antimicrob Chemother","first-page":"240","volume":"55","year":"2005","unstructured":"Lipsky BA, Stoutenburgh U: Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. .J Antimicrob Chemother55::240. ,2005. .15659542"},{"key":"R71","series-title":"Antimicrob Agents Chemother","first-page":"2680","volume":"50","year":"2006","unstructured":"Denis O, Deplano A, Nonho C: In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. .Antimicrob Agents Chemother50::2680. ,2006. .16870758"},{"key":"R72","series-title":"Antimicrob Agents Chemother","first-page":"3959","volume":"50","year":"2006","unstructured":"Goldstein EJC, Citron DM, Merriam CV: In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. .Antimicrob Agents Chemother50::3959. ,2006. .16982780"},{"key":"R73","series-title":"Ann Pharmacother","first-page":"501","volume":"29","year":"1995","unstructured":"Schoonover LL, Occhipinti DJ, Rodvold KA, et al: Piperacillin\/tazobactam: a new \u03b2-lactam\/\u03b2-lactamase inhibitor combination. .Ann Pharmacother29::501. ,1995. .7655135"},{"key":"R74","series-title":"Surg Infect (Larchmt)","first-page":"419","volume":"6","year":"2005","unstructured":"Ong CT, Kuti JL, Nicolau DP, et al: Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. .Surg Infect (Larchmt)6::419. ,2005. ."},{"key":"R75","series-title":"Expert Opin Investig Drugs","first-page":"419","volume":"16","year":"2007","unstructured":"Bush K, Heep M, Macielag MJ, et al: Anti-MRSA \u03b2-lactams in development, with a focus on ceftobiprole: the first MRSA \u03b2-lactam to demonstrate clinical efficacy. .Expert Opin Investig Drugs16::419. ,2007. .17371191"},{"key":"R76","series-title":"Clin Microbiol Infect","first-page":"25","volume":"13","year":"2007","unstructured":"Noel GJ: Clinical profile of ceftobiprole, a novel \u03b2-lactam antibiotic. .Clin Microbiol Infect13::25. ,2007. ."},{"key":"R77","series-title":"Antimicrob Agents Chemother","first-page":"2773","volume":"53","year":"2009","unstructured":"Barbour A, Schmidt S, Sabarinath SN, et al: Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. .Antimicrob Agents Chemother53::2773. ,2009. .19364847"},{"key":"R78","series-title":"Diagn Microbiol Infect Dis","first-page":"96","volume":"61","year":"2008","unstructured":"Lodise T, Patel N, Renaud-Mutart A, et al: Pharmacokinetic and pharmacodynamic profile of ceftobiprole. .Diagn Microbiol Infect Dis61::96. ,2008. .18384996"},{"key":"R79","series-title":"Antimicrob Agents Chemother","first-page":"3371","volume":"53","year":"2009","unstructured":"Kimko H, Xu X, Nandy P, et al: Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. .Antimicrob Agents Chemother53::3371. ,2009. .19528285"},{"key":"R80","series-title":"J Antimicrob Chemother","first-page":"ii83","volume":"53","year":"2004","unstructured":"Tice AD: Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. .J Antimicrob Chemother53: (suppl 2):ii83. ,2004. .15150187"},{"key":"R81","series-title":"Diagn Microbiol Infect Dis","first-page":"129","volume":"43","year":"2002","unstructured":"Pelak BA, Bartizal K, Woods GL, et al: Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections. .Diagn Microbiol Infect Dis43::129. ,2002. .12088620"},{"key":"R82","series-title":"J Antimicrob Chemother","first-page":"ii51","volume":"53","year":"2004","unstructured":"Solomkin J, Teppler H, Graham DR, et al: Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. .J Antimicrob Chemother53: (suppl 2):ii51. ,2004. .15150183"},{"key":"R83","series-title":"Antimicrob Agents Chemother","first-page":"1222","volume":"50","year":"2006","unstructured":"Chen M, Nafziger A, Drusano G, et al: Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese and extremely obese adults. .Antimicrob Agents Chemother50::1222. ,2006. .16569832"},{"key":"R84","series-title":"J Antimicrob Chemother","first-page":"680","volume":"58","year":"2006","unstructured":"Kaka AS, Rueda AM, Shelburn SA: Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. .J Antimicrob Chemother58::680. ,2006. .16840428"},{"key":"R85","series-title":"Clin Infect Dis","first-page":"S63","volume":"24","year":"1997","unstructured":"Huovinen P: Increases in rates of resistance to trimethoprim. .Clin Infect Dis24::S63. ,1997. .8994780"},{"key":"R86","series-title":"Clin Infect Dis","first-page":"735","volume":"47","year":"2008","unstructured":"Shehab N, Patel PR, Srinivasan A, et al: Emergency department visits for antibiotic-associated adverse events. .Clin Infect Dis47::735. ,2008. .18694344"},{"key":"R87","series-title":"Ann Pharmacother","first-page":"1693","volume":"40","year":"2006","unstructured":"Carter MK, Ebers VA, Younes BK: Doxycycline for community-associated methicillin-resistant Staphylococcus aureus skin and soft-tissue infections. .Ann Pharmacother40::1693. ,2006. ."},{"key":"R88","series-title":"Clin Infect Dis","first-page":"1429","volume":"40","year":"2005","unstructured":"Ruhe JJ, Monson T, Bradsher RW: Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. .Clin Infect Dis40::1429. ,2005. .15844065"},{"key":"R89","year":"2005","unstructured":"Tigecycline [package insert], Wyeth Pharmaceuticals, Philadelphia, June. 2005. ."},{"key":"R90","series-title":"Clin Ther","first-page":"1079","volume":"28","year":"2006","unstructured":"Doan TL, Fung HB, Mehta D, et al: Tigecycline: a glycylcyclines antimicrobial agent. .Clin Ther28::1079. ,2006. .16982286"},{"key":"R91","series-title":"Int J Infect Dis","first-page":"S7","volume":"11","year":"2007","unstructured":"Grolman DC: Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. .Int J Infect Dis11: (suppl 1):S7. ,2007. .17603950"},{"key":"R92","series-title":"Br J Clin Pharmacol","first-page":"235","volume":"48","year":"1999","unstructured":"van der Linden PD, van de Lei J, Nab HW, et al: Achilles tendinitis associated with fluoroquinolones. .Br J Clin Pharmacol48::235. ,1999. ."},{"key":"R93","series-title":"BMJ","first-page":"1306","volume":"324","year":"2002","unstructured":"van der Linden PD, Sturkenboom MC, Herings RM, et al: Fluoroquinolones and risk of Achilles tendon disorders: case-control study. .BMJ324::1306. ,2002. .12039823"},{"key":"R94","series-title":"Am J Med Sci","first-page":"334","volume":"331","year":"2006","unstructured":"Wang S, Rizvi AA: Levofloxacin-induced hypoglycemia in a nondiabetic patient. .Am J Med Sci331::334. ,2006. .16775443"},{"key":"R95","series-title":"Ann Emerg Med","first-page":"160","volume":"36","year":"2000","unstructured":"Roberge RJ, Kaplan R, Frank R, et al: Glyburide-ciprofloxacin interaction with resistant hypoglycemia. .Ann Emerg Med36::160. ,2000. .10918110"},{"key":"R96","series-title":"Int J Antimicrob Agents","first-page":"357","volume":"26","year":"2005","unstructured":"Giordano P, Song J, Pertel P, et al: Sequential intravenous\/oral moxifloxacin versus intravenous pipercillin-tazobactam followed by oral amoxicillin-clavulanate for treatment of complicated skin and skin structure infection. .Int J Antimicrob Agents26::357. ,2005. .16229991"},{"key":"R97","series-title":"J Antimicrob Chemother","first-page":"836","volume":"54","year":"2004","unstructured":"Oberdorfer K, Swoboda S, Hamann A, et al: Tissue and serum levofloxacin concentrations in diabetic foot infection patients. .J Antimicrob Chemother54::836. ,2004. .15375105"},{"key":"R98","series-title":"Antimicrob Agents Chemother","first-page":"3099","volume":"47","year":"2003","unstructured":"Joukhadar C, Stass H, Muller-Zellenberg U, et al: Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. .Antimicrob Agents Chemother47::3099. ,2003. .14506015"},{"key":"R99","series-title":"Clin Pharmacol Ther","first-page":"532","volume":"70","year":"2001","unstructured":"Joukhadar C, Klein N, Frossard M, et al: Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. .Clin Pharmacol Ther70::532. ,2001. .11753269"},{"key":"R100","series-title":"Dermatol Online J","first-page":"6","volume":"12","year":"2006","unstructured":"Scheinfeld N: Dalbavancin: a review for dermatologists. .Dermatol Online J12::6. ,2006. ."},{"key":"R101","series-title":"Pharmacotherapy","first-page":"908","volume":"26","year":"2006","unstructured":"Pope SD, Roecker AM: Dalbavancin: a novel lipoglycopeptide antibacterial. .Pharmacotherapy26::908. ,2006. .16803423"},{"key":"R102","series-title":"Clin Infect Dis","first-page":"1298","volume":"37","year":"2003","unstructured":"Seltzer E, Dorr MB, Goldstein BP, et al: Dalbavancin skin and soft-tissue infection study group: once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. .Clin Infect Dis37::1298. ,2003. .14583862"},{"key":"R103","series-title":"Clin Infect Dis","first-page":"1407","volume":"41","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E, et al: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. .Clin Infect Dis41::1407. ,2005. .16231250"},{"key":"R104","series-title":"Antimicrob Agents Chemother","first-page":"862","volume":"50","year":"2006","unstructured":"Stryjewski ME, Chu VH, O\u2019Riordan WD, et al: Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections caused by gram-positive bacteria: FAST 2 study. .Antimicrob Agents Chemother50::862. ,2006. .16495243"},{"key":"R105","series-title":"Expert Rev Anti Infect Ther","first-page":"743","volume":"4","year":"2006","unstructured":"Kanafani ZA: Telavancin: a new lipoglycopeptide with multiple mechanisms of action. .Expert Rev Anti Infect Ther4::743. ,2006. .17140351"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/japmaonline.org\/view\/journals\/apms\/100\/1\/1000052.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/100\/1\/52\/1404585\/1000052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/100\/1\/1000052.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/100\/1\/1000052.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:11:45Z","timestamp":1783505505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/100\/1\/52"}},"subtitle":["A Review with an Emphasis on Tissue Penetration Characteristics"],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":105,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.7547\/1000052","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}